Last 31.75 GBp
Change Today 0.00 / 0.00%
Volume 114.2K
SCLP On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

Open
31.75 GBp
Previous Close
31.75 GBp
Day High
31.75 GBp
Day Low
31.75 GBp
52 Week High
12/9/13 - 46.25 GBp
52 Week Low
11/8/13 - 27.00 GBp
Market Cap
71.4M
Average Volume 10 Days
202.7K
EPS TTM
-0.01 GBp
Shares Outstanding
225.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC operates as a biopharmaceutical company in the United Kingdom. The company, through its subsidiary, Scancell Limited, engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody and Moditope platforms. It develops SCIB1, a plasmid DNA vaccine, which is in phase II clinical trials for the treatment of melanoma; and SCIB2 that stimulates immune responses to the lung cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; ImmuneRegen BioSciences, Inc; NIH; ImmunoVaccine Technologies; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC is based in London, the United Kingdom.

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 7.5K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 7.5K GBP
Compensation as of Fiscal Year 2013.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings PLC Announces Audited Consolidated Earnings Results for the Year Ended April 30, 2014

Scancell Holdings PLC announced audited consolidated earnings results for the year ended April 30, 2014. For the year, the company's operating loss was GBP 2,497,220 against GBP 2,183,989 a year ago. Loss before taxation was GBP 2,468,034 against GBP 2,153,952 a year ago. Loss and total comprehensive income was GBP 2,222,954 or 1.03 pence per basic and diluted share against GBP 1,901,944 or 0.98 pence per basic and diluted share a year ago. Net cash used in operating activities was GBP 2,093,367 against GBP 1,998,331 a year ago. Asset acquisition was GBP 22,930 against GBP 69,393 a year ago.

Scancell Holdings plc Announces New Data Demonstrating on SCIB1 with Checkpoint Inhibitors

Scancell Holdings plc announced new data demonstrating that animals treated with a combination of SCIB1, Scancell's ImmunoBody® vaccine in development for the treatment of melanoma, and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. The company had previously shown that administration of SCIB1 alone induced potent tumour-specific T cell responses associated with increased T cell infiltration into the tumour and enhanced proliferation of T cells within the tumour resulting in tumour rejection and long-term survival in 50% of animals. In its new study, PD-1 blockade, when used alone, resulted in tumour rejection and long-term survival in 55% of animals. However, the combination of PD-1 blockade with SCIB1 vaccination further enhanced T cell infiltration, resulting in tumour rejection and long-term survival in 85% of animals. These results highlight the potential benefits of combining SCIB1 with PD-1 blockade in the treatment of cancer. Checkpoint inhibitors can enable the host immune system to recognise, attack and destroy cancer cells. However, checkpoint inhibitors cannot work on their own if the patient fails to mount an adequate immune response to the tumour. Taking the brake off immunosuppressive T cells with PD-1 blockade, whilst simultaneously pressing the accelerator with active immunotherapies such as SCIB1 is increasingly regarded as the logical next step towards overwhelming the disease and increasing efficacy. These data confirm for the first time that the combination of SCIB1 with PD-1 blockade enhances tumour destruction and prolongs survival in animal models.

Scancell Holdings plc Announces Update on Phase 1/2 Trial of SCIB1 in Melanoma

Scancell Holdings plc announced further encouraging results from its on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBody. The updated data was presented in a poster at the 2014 American Society of Clinical Oncology (ASCO) meeting in Chicago on Sunday 1 June 2014. The Phase 1/2 trial is an open label, non-randomised study to determine the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electroporation device. While the primary objective of the study is to access safety and tolerability, the secondary objectives are to evaluate cellular immune responses and to assess any tumour response. Part 1 higher dose 8mg study interim results (Stage IV disease only): All five patients with Stage IV disease remain alive with a median survival time of 11 months from study entry (range 8-12 months); One patient in this cohort has shown a pronounced reduction in lung metastases following SCIB1 treatment, meeting the RECIST criteria for a partial response by Week 9 of treatment and has started continuation treatment. This is the second patient in the study to show an objective clinical response; A further patient with breast and lung lesions at study entry remained stable for 6 months and is continuing treatment with SCIB1; Four of the five patients produced an immune response to SCIB1; Immune responses to the 8mg dose, measured by Elispot, were up to 10-fold higher than those seen in the lower dose 4mg group; high frequencies of melanoma-specific T cells exceeding 2% of total blood lymphocytes were observed. Part 1 lower dose 2mg/4mg study update (Stage III/IV disease): The four patients (of six) who were alive at the time of the December 2012 Part 1 report remain alive; One patient had multiple tumour lesions which disappeared or decreased in size except for one lesion which was resected; the patient, who is still alive, has subsequently developed another lesion which was also resected; Two further patients have remained disease-free for 18 and 35 months respectively, having required regular treatment and resection of metastases prior to SCIB1 treatment; Median survival time in Part 1 patients who received at least three treatments with the 2mg/4mg doses of SCIB1 is now 30 months from study entry and 49 months since diagnosis of metastatic disease; Five of six patients receiving 2mg/4mg doses of SCIB1 produced an immune response. Part 2 study update (Stage III/IV patients with resected tumours): All 14 study patients produced an immune response to SCIB1 treatment; All patients are still alive after being on the study for between 16 and 24 months; Only three patients have any evidence of disease progression after 4, 14 and 18 months on the study; Median survival time of all Part 2 patients since initiating treatment is currently 21 months and 26 months since diagnosis of metastatic disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 31.75 GBp 0.00

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies
 

Industry Analysis

SCLP

Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCANCELL HOLDINGS PLC, please visit www.scancell.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.